The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.
暂无分享,去创建一个
Mark E Bunnage | M. Bunnage | David A. Price | A. Brown | M. Trevethick | R. A. Lewthwaite | P. Glossop | David A Price | R. Webster | Kim James | Rhys M. Jones | Christelle Perros-Huguet | Mike Trevethick | Rob Webster | S. Mantell | Alan D Brown | Rhys Jones | Paul A Glossop | Charlotte A L Lane | Russell A Lewthwaite | Simon Mantell | K. James | C. Lane | C. Perros-Huguet
[1] G. Anderson. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.
[2] A. Tattersfield,et al. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. , 1999, The European respiratory journal.
[3] J C Yernault,et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.
[4] R. A. Coleman,et al. Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterol , 1993, British journal of pharmacology.
[5] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .
[6] B. Waldeck. Beta-adrenoceptor agonists and asthma--100 years of development. , 2002, European journal of pharmacology.
[7] R. Austin,et al. QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.
[8] J. Lötvall,et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.
[9] Alan Daniel Brown,et al. The discovery of long acting β2-adrenoreceptor agonists , 2007 .